EuroBiotech Report—GW’s trial fail, Arix-Ipsen, Medigene T-cell trial and Santhera in DMD

(CC0 Public Domain)

Welcome to the latest edition of our weekly EuroBiotech Report. We start this week with weak data from GW Pharmaceuticals. The cannabinoid specialist saw GWP42006 fall short in a midphase focal seizure trial, but it is holding out hope the drug can go on to shine in autism spectrum disorders. In the U.K., Arix Bioscience added Ipsen to its growing stable of pharma partners. Medigene got the all-clear to start testing its T-cell receptor therapy in humans. Santhera, wounded by regulatory blows, secured the chance to offer Raxone to Duchenne muscular dystrophy patients through an expanded access program. And more.—Nick Taylor  

1. GW cannabinoid drug fails midphase epilepsy trial

GW Pharmaceuticals’ GWP42006 failed to outperform placebo in a phase 2a focal seizure trial. The setback wiped 5% off GW’s stock and dented the prospects of the cannabidivarin candidate.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

2. Ipsen joins Arix’s growing pool of pharma partners

Ipsen has become the latest drugmaker to start working with Arix Bioscience. The French biopharma follows Fosun, Takeda and UCB to become the fourth company to secure a connection to Arix’s stable of startups.

3. Medigene gets OK for first trial of T-cell receptor therapy

Medigene has been given a green light by regulators in Germany to start human trials of MDG1011, the lead candidate to come out of its modified T-cell program.

4. Santhera offers Raxone to U.S. DMD patients through expanded access program

Santhera has suffered several regulatory setbacks around Raxone (idebenone) in Duchenne muscular dystrophy. In lack of official approvals, the company is offering the drug for patients in the U.S. through an expanded access program operated by Clinigen.

And more articles of note>>

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.